SARS-CoV-2 specific immunity in patients with congenital immune deficiencies

SARS-CoV-2 specific immunity in patients with congenital immune deficiencies - SARS-CoV-2 immUNity in immune deficieNcY (SUNNY)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50905

Enrollment

Registered

2021-01-24

Start date

2021-02-09

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 immunity immune response against SARS-CoV-2

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - congenital immune disorder for with they are monitored at the Infectious Diseases outpatient clinic of the LUMC - PCR-confirmed COVID-19 in the past or present

Exclusion criteria

Exclusion criteria: - received a covid-19 vaccination before start of the study, regardless of the type of vaccine or vaccine manufacturer

Design outcomes

Primary

Measure	Time frame
1. SARS-CoV-2 specific T-cell immunity 2. SARS-CoV-2 neutralizing antibodies 3. SARS-CoV-2 response after vaccination	—

Secondary

Measure	Time frame
None	—

Countries

Netherlands

Outcome results